Artcline

Executive Summary

Artcline is a German biotech company developing innovative immune cell-based therapies for critical care, with a primary focus on extracorporeal sepsis therapy. Its flagship product, ARTICE® Therapy, targets bacterial sepsis, a leading cause of mortality in intensive care units. The company leverages over 15 years of experience in translating academic research into industrial applications and is currently conducting advanced clinical trials for ARTICE®. Sepsis represents a massive global unmet medical need, with limited effective treatments available, positioning Artcline's technology as a potentially transformative intervention in critical care medicine. ARTICE® Therapy is an extracorporeal immune cell therapy designed to modulate the host's inflammatory response and eliminate pathogens. If successful, it could become the standard of care for sepsis, reducing mortality and improving outcomes in ICUs. Artcline is well-positioned as a leader in this niche, with a differentiated approach compared to traditional drug-based therapies. The company's progress through advanced clinical trials suggests a clear regulatory path ahead, making it a compelling investment opportunity in the cell and gene therapy space.

Upcoming Catalysts (preview)

• Q4 2026Phase II/III Data Readout for ARTICE® Therapy65% success
• Q2 2027Regulatory Submission (EMA) for ARTICE® Therapy55% success